BACKGROUND: @entity1 with @entity740 ( @entity740 ) have worse outcomes during and after percutaneous coronary interventions (PCI). Abciximab reduces complications, but may cause excessive @entity548 in @entity1 with @entity740 . Therefore, we sought to determine the safety of abciximab in @entity1 with @entity740 . METHODS: @entity1 (n = 4158) undergoing PCI at the Mayo Clinic since abciximab became available were analyzed according to their estimated @entity1011 clearance (> or =70, 50-69, or <50 mL/min) or need for dialysis. @entity548 was defined as a cerebrovascular bleed or a decrease in the hematocrit level >15%. @entity548 was defined as a decrease in the hematocrit level of 10% to 15% with an identifiable site of @entity548 . RESULTS: @entity740 was associated with @entity548 in @entity1 who received abciximab and @entity1 who did not. However, there was only a trend toward an interaction between @entity1011 clearance and @entity548 with abciximab (odds ratio [OR], 1.18; P =.06) and no interaction with minor @entity548 (OR, 1.01; P =.94) or any @entity548 (OR, 1.10; P =.15). CONCLUSION: @entity740 is associated with an increased risk of @entity548 complications after PCI. Although abciximab increases the risk of @entity548 in all @entity1 , the increase in relative risk is not significantly greater in @entity1 with @entity740 . Thus, abciximab may be given safely in @entity1 with @entity740 who are undergoing PCI.

Safety of abciximab in XXXX with @entity740 who are undergoing percutaneous coronary interventions.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine'] @entity740 :: ('MESH:D051436', 'Disease') :: ['chronic renal insufficiency', 'CRI'] @entity548 :: ('MESH:D006470', 'Disease') :: ['Minor bleeding', 'Major bleeding', 'increased bleeding', 'bleeding', 'major bleeding']
@entity1 :: (9606,Species) :: ['patients']
